CTKB Cytek Biosciences, Inc.
Healthcare$4.00+0.00%OpenMarket Cap: $517.2M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.58
P/S
2.54
EV/EBITDA
-20.79
DCF Value
$0.82
FCF Yield
-2.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
51.7%
Operating Margin
-21.5%
Net Margin
-36.2%
ROE
-20.8%
ROA
-16.5%
ROIC
-11.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $44.1M | 48.2% | $-18.5M | $-18.9M | $— | — |
| Q4 null | $62.1M | 52.9% | $-5.6M | $-44.1M | $— | — |
| FY null | $201.5M | 51.8% | $-40.4M | $-66.5M | $— | — |
| Q3 null | $52.3M | 52.7% | $-9.2M | $-5.5M | $— | — |
| Q2 null | $45.6M | 52.3% | $-10.6M | $-5.6M | $— | — |
| Q1 null | $41.5M | 48.6% | $-15.0M | $-11.4M | $— | — |
| Q4 null | $57.5M | 58.5% | $3.0M | $9.6M | $— | — |
| FY null | $200.5M | 55.4% | $-20.5M | $-6.0M | $— | — |
| Q3 null | $51.5M | 56.3% | $-4.2M | $941.0K | $— | — |
| Q2 null | $46.6M | 54.6% | $-8.5M | $-10.4M | $— | — |
| Q1 null | $44.9M | 51.3% | $-10.7M | $-6.2M | $— | — |
| Q4 2023 | $58.2M | 56.8% | $-137.0K | $5.5M | $0.04 | — |